OMEROS CORP 10-K — AI Bull & Bear Analysis

The 10-K reveals a company in the midst of a high-stakes transition. Omeros has successfully traded a diversified but risky pipeline for a concentrated commercial bet and a strengthened balance sheet. The immediate financial pressure has eased due to the Novo Nordisk transaction, but the fundamental challenge remains: converting regulatory approval into sustainable, scalable revenue. Investors are now weighing the asymmetric upside of YARTEMLEA's unique safety profile against the systemic risks of a single-product company with significant legacy liabilities. The ability of the company to execute its commercial launch without further diluting shareholders will be the primary determinant of its long-term viability.